The mechanisms by which macromolecules are transported through the cell wall of fungi are not known. A central question in the biology of Cryptococcus neoformans, the causative agent of cryptococcosis, is the mechanism by which capsular polysaccharide synthesized inside the cell is exported to the extracellular environment for capsule assembly and release. We demonstrate that C. neoformans produces extracellular vesicles during in vitro growth and animal infection. Vesicular compartments, which are transferred to the extracellular space by cell wall passage, contain glucuronoxylomannan (GXM), a component of the cryptococcal capsule, and key lipids, such as glucosylceramide and sterols. A correlation between GXM-containing vesicles and capsule expression was observed. The results imply a novel mechanism for the release of the major virulence factor of C. neoformans, whereby polysaccharide packaged in lipid vesicles crosses the cell wall and the capsule network to reach the extracellular environment.
Introduction
Cryptococcus neoformans is a yeast-like pathogenic fungus that is the etiologic agent of human cryptococcosis. Infection is usually asymptomatic and restricted to the lung in immunocompetent individuals, but fungal cells can disseminate to other organs and cause cryptococcal meningoencephalitis, a common syndrome in immunosuppressed patients (29, 39) .
Significant progress in our understanding of how C. neoformans causes disease was made in the last decade, but many aspects of cryptococcal pathogenesis remain poorly understood.
C. neoformans represents a unique model in cell biology studies because it is the only eukaryotic pathogen with a polysaccharide capsule, a structure that is essential for virulence (4, 19) . The major capsular polysaccharide, glucuronoxylomannan (GXM), has an average mass ranging from 1.7 to 7 x 10 6 daltons (22) and is released extracellularly during infection, inducing a number of deleterious effects to the host (39) . GXM also represents a potential vaccine component and is the target of therapeutic antibodies that are currently in clinical trial (3, 8, 20, 27 ).
The fungal cell wall is a compact, albeit dynamic, structure that plays important roles in several biological processes determining cell shape, morphogenesis, reproduction, cell-cell and cell-matrix interaction, osmotic and physical protection (25) . Although the relevance of the cell wall to fungal physiology and pathogenesis is clear, the mechanisms by which large molecules (molecular weight > 1 million) cross this rigid structure to reach the extracellular environment are largely unknown. In C. neoformans, it has been suggested that capsule components containing epitopes recognized by a monoclonal antibody (mAb) to GXM are synthesized intracellularly and exported through the cell wall, possibly inside membrane vesicles (11). These results were validated in a recent study using a secretion mutant of C. neoformans, in which post-
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Materials and Methods
Culture conditions. The cryptococcal isolates used in this study comprised strains ATCC 24067
(serotype D, American Type Culture Collection), H99 (serotype A, clinical isolate), HEC3393
(serotype A, clinical isolate), and Cap67 (acapsular mutant). In the different analyses performed, similar data were obtained with encapsulated strains. Except for the presence of GXM, results in assays using acapsular cells also followed the same profile obtained with HEC3393, H99 and 24067 cells. For vesicle purification, C. neoformans cells were inoculated into 1000 ml
Erlenmeyer flasks containing 400 ml of a minimal medium composed of dextrose (15 mM), concentrated by approximately 20-fold using an Amicon ultrafiltration system (cutoff = 100 kDa). To ensure the removal of cells and cellular debris, the concentrated culture fluid was again centrifuged as described above and the resulting supernatant was then centrifuged at 100,000 g for 1 h at 4 o C. The supernatants were then discarded and pellets were washed by five sequential resuspension and centrifugation steps, each consisting of 100,000 g for 1 h at 4 o C with 0.1M tris buffered saline (TBS). The pellets were then resuspended in fixative solution for electron
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8 fraction was recovered by centrifugation. This process was repeated three times and GXM content in different fractions was analyzed by capture ELISA, as described below.
Sucrose gradient. Sucrose density centrifugation was performed as described by Gutwein et al.
(15). The vesicle suspension (0.5 ml) obtained after ultracentrifugation and purification with the antibody-coupled resin was mixed with an equivalent volume of 85% sucrose (w/v in TBS), generating a final concentration of 42.5% sucrose. This suspension was transferred to an ultracentrifuge tube and a step gradient was prepared by overlaying the original suspension with Lipid analysis. Pellets obtained from centrifugation of cell supernatants at 100,000 g were first suspended in methanol and then two volumes of chloroform were added. The mixture was vigorously vortexed and centrifuged to discard precipitates, dried by vacuum centrifugation and partitioned according to Folch et al. (13) . The lower phase, containing neutral lipids, was recovered for analysis by high performance thin layer chromatography (HPTLC). For sterol
analysis, the lipid extract was loaded into HPTLC silica plates (Si 60F254s, LiChrospher, Germany) and separated using a solvent system containing hexane:ether:acetic acid (80:40 The lower phase obtained after Folch's partition was also analyzed by electrospray ionization-mass spectrometry (ESI-MS) using a Finnigan LCQ-Duo ion trap instrument (Thermo Electron, San Jose, CA). Samples were diluted in chloroform-methanol (1:1, vol/vol), containing 10 mM lithium iodide, and introduced into ESI-MS at 10 µl/min flow rate, with the assistance of an infusion micropump (Harvard Apparatus, Cambridge, MA). Analyses were carried out in the positive (ESI+) mode. The source and capillary voltages were 4.5 kV and 3 V, respectively. The capillary temperature was kept at 200°C. Spectra were collected at a 300-to 800-m/z range.
Source-induced dissociation was obtained at 25 V. Ion trap collision-induced dissociation (ESI-MS/MS) experiments were carried out at 20 to 60% (1 to 3 eV) normalized relative collision energy. All spectra were processed using the Xcalibur software (Thermo Electron).
Lipids in fractions from the sucrose gradient were analyzed by high performance liquid chromatography (HPLC) in a Waters 600 liquid chromatograph (New York, NY), using an Alltech C 18 column (Deerfield, IL) (250 x 4.6 mm dimensions, 5 µm particle size). A mixture of chloroform and methanol (9:1, v/v) was used as the mobile phase and lipid components were
detected by absorbance at 280 nm in a Waters 486 detector. The profile of elution of lipids from sucrose gradient fractions was compared with a standard of purified cryptococcal GlcCer (30) . A C C E P T E D min. Cell viability was evaluated by inoculating control or treated yeasts onto Sabouraud dextrose agar (SDA) and counting of colony forming units (CFU). After incubation in the conditions described above, yeasts were removed as described previously in this section and the supernatants ultracentrifuged at 100,000 g. The resulting pellets were extracted with mixtures of chloroform-methanol 2:1 (for GlcCer analysis) or 9:1 (for sterol analysis). Extracts were analyzed by HPTLC following the conditions described in "Lipid analysis".
Serological assays for GXM detection. The profiles of GXM distribution in the fractions obtained after sucrose density centrifugation were analyzed by using a capture enzyme-linked immunosorbent assay (ELISA) (2) . Briefly, each well of a 96-well polystyrene plate was coated with a goat anti-mouse IgM. After removal of unbound antibodies, a solution of mAb 12A1, an
IgM mAb with specificity for GXM, was added to the plate, and this step was followed by blocking with 1% bovine serum albumin.
The ELISA was used to analyze vesicles after treatment with methanol and chloroform, as described in "Lipid analysis". Purified GXM was used as a positive control. The samples were incubated in the plate overnight at 4°C. The plates were then washed five times with a solution of TBS supplemented with 0.1% Tween 20, followed by incubation with mAb 18B7 for 1 h. The plate was again washed and incubated with an alkaline phosphatase-conjugated goat anti-mouse IgG1 for 1 h. Reactions were developed after the addition of p-nitrophenyl phosphate disodium hexahydrate, followed by reading at 405 nm with a Multiscan MS (Labsystem, Helsinki, Finland). Antibodies in this assay were all used at a concentration of 1 µg/ml. Capsule induction. Capsule expression in C. neoformans was induced as described (42) .
Briefly, C. neoformans was inoculated in Sabouraud broth diluted 10 times in MOPS 50 mM, pH 7.3. After incubation for 6 or 24 h at 37 o with shaking, the cells were recovered by centrifugation for 10 min at 2,000 g and fixed in 2% paraformaldehyde in TBS. The fixative agent was removed by washing with PBS and, after staining with India ink, capsule expression was analyzed microscopically. Capsule sizes, defined as the distances between the cell wall and the outer border of the capsule, were determined by using the ImageJ Software, elaborated and provided by National Institutes of Health (NIH, http://rsb.info.nih.gov/ij/). All experiments were performed in triplicate sets and the results analyzed by using Student's t test. Supernatantassociated vesicles produced as described above were then purified by affinity chromatography and different centrifugation steps, as described previously in this section. GXM concentration in Yeast cells were finally observed with an Axioplan 2 (Zeiss, Germany) fluorescence microscope.
Images were acquired using a Color View SX digital camera and processed with the software system analySIS (Soft Image System). In control systems, mAb 18B7 was replaced by irrelevant antibodies. In addition, vesicle preparations were simply removed from the experimental system (negative control) or replaced by soluble, non-vesicular GXM (positive control), purified as described elsewhere (6) .
Production of GXM-containing vesicles during the in vitro infection of macrophages with
C. neoformans. The ability of cryptococci to produce GXM-containing vesicles during the infection of host cells was evaluated using the J774.16 cell line, which has been extensively used to study C. neoformans-mouse macrophage interactions. Macrophage-like cells were cultured in DMEM supplemented with 10% FCS, 10% NCTC-109, and 1% nonessential amino acids, at 37°C in a 5% CO 2 atmosphere. Cultures were also supplemented with 100 U/ml IFN-γ and 1
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µg/ml LPS. The cells were grown to confluence in 75 cm 2 flasks and then infected with C.
neoformans (10 yeast per host cell) in the presence of 10 µg/ml of mAb 18B7, which binds to the capsular polysaccharide and is opsonic (3). After 1 h of incubation at 37 0 C, free C. neoformans cells were removed by washing. Based on the observation that J774.16 cells lyse after hosting intracellular replication of cryptococci (38) , washed infected cells were incubated for 18 h at 37 0 C. Host cell lysis and cryptococcal intracellular replication were observed microscopically.
Fluids from infected cultures were then analyzed for vesicles as described above. These results implied that cryptococcal vesicles could pass through the cell wall to be released to the extracellular environment. Consequently, we hypothesized that these structures would be found in culture supernatants. Transmission electron microscopy of material recovered by concentration of C. neoformans culture supernatants followed by differential sedimentation revealed the presence of vesicular bodies ( Figure 1F-H) . Vesicle size and electron density varied considerably but, essentially, all of them corresponded to spherical bodies with evident bilayered membranes.
Results
Production
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GlcCer and sterols are present in vesicular lipid extracts. Pellets obtained after centrifugation of culture supernatants at 100,000 g were extracted with different mixtures of organic solvents and these preparations were analyzed by HPTLC. In different vesicle preparations, bands with migration rates corresponding to the GlcCer standard were detected in lipid extracts from both acapsular and encapsulated C. neoformans cells (Figure 2, inset) . Vesicular extracts from both encapsulated and acapsular isolates also present molecules with R f corresponding to ergosterol, the principal fungal sterol. In order to confirm that sterols and GlcCer are in fact the molecules detected by HPTLC analysis, vesicle lipids from encapsulated cells were examined by ESI (MS and MS/MS) in positive mode. Although several molecular ions were detected (Figure 2 ), the analysis was focused on sterols and GlcCer, the major species detected in TLC analysis. were also observed. All of these peaks were compatible with a monolithiated molecular ion corresponding to an obtusifoliol-like molecule lacking the double bond between carbons 8 and 9.
The principal cerebroside produced by C. neoformans is N-2'-hydroxyoctadecanoyl-1-
This structure was therefore identified as 4,14-dimethylergosta-24(24 1 )-en-3β-ol.
Vesicle production requires viable C. neoformans cells. After growth for 72 h, the viability of the cryptococcal population was very close to 100%, as determined by PI staining (data not shown). However, even with high indices of viability, the possibility that the vesicles originated from a minor fraction of dead cells could not be discarded. In this context, we first evaluated the ability of C. neoformans to use radioactive precursors of ceramide to produce 
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corresponding products in vesicular preparations. The insignificant levels of [ 3 H]GlcCer detection in sterile media containing the radioactive precursors and in 100,000 g supernatants supported this hypothesis. In addition, GlcCer-containing vesicles being transferred from the plasma membrane to the cell wall were detected by immunogold labeling with antibodies to
GlcCer followed by analysis by TEM ( Figure 3B ). Wall-associated extracellular vesicular bodies were also observed in these preparations.
The possibility that the vesicles could be the products of dead cells was also considered,
given that lipids are present in the membranes of all organelles. Thus, we compared lipid profiles obtained in regular vesicle fractions with those obtained from dead cells. To avoid false negative results, several methods of fungal killing were evaluated, including metabolic inhibition (sodium azide treatment) and protein denaturation (mild heat exposure). C. neoformans was grown under the conditions used for vesicle production, and then the supernatant was collected and used for vesicle purification. Cell viability decreased by 83 and 99 %, respectively, after treatment with azide or heat ( Figure 3C ). The treated yeast cells were removed as described in Experimental
Procedures and the supernatants centrifuged at 100,000 g. GlcCer was detected in 100,000 g fractions from living, but not heat-or azide-treated cells, as determined by HPTLC using a purified standard of ceramide monohexoside. Sterol analysis revealed that compounds with migration rates corresponding to an ergosterol standard were detected in 100,000 g fractions from supernatants of living and azide-treated cells, but not in preparations from heat-killed cryptococci. We speculate that the detection of sterols in vesicles from azide-treated cells could be the result of stress-associated secretory activity during metabolic inhibition. Also, the sterol content of 100,000 g fractions from living and azide-treated cells was analyzed by densitometry,
showing that the detection of sterol in the former was 2.5 fold higher (data not shown). In summary, these results suggest that the vesicles described here are produced and excreted by living C. neoformans, rather than released from dead cells. Results using the different strains currently studied were very similar.
GXM is contained inside cryptococcal vesicles. The presence of GXM in vesicular bodies was evaluated by immunogold labeling of purified vesicles with mAb 18B7 followed by TEM analysis ( Figure 4A ). Antibody binding to purified vesicles was largely concentrated in the vesicular matrix. The presence of GXM was confirmed by the fact that the antibody reacted strongly with their contents (obtained by solvent-mediated lysis) in ELISA tests ( Figure 4B ). As an additional control, the supernatant obtained before vesicle lysis was also assayed, and the content of GXM in this preparation was around 10-fold lower than the amount of GXM in the vesicle pellet. The most straightforward interpretation of these results is that GXM is contained primarily in the intravesicular compartment, but that some material is found in solution, probably as a result of vesicle damage and/or disruption in handling. To confirm the premise that GXM was intravesicular, we removed the extracellular GXM by sequential passage of the vesicle preparation over a column of Sepharose-bound mAb 18B7 ( Figure 4C ). In this experiment, the vesicle fraction and a vesicle-depleted supernatant were consecutively passed through the antibody-containing resin. While the GXM content in the supernatant seemed to decrease after each step of incubation with the resin, it stabilized when the vesicle preparation was used.
Hence, we conclude that the vesicles contain GXM.
To exclude the possibility that GXM-containing vesicles were formed extracellularly by random incorporation of the polysaccharide into liposomes instead of being secreted, the 
GXM content in vesicles correlates with capsule synthesis. If GXM was packaged inside
vesicles for extracellular transport we hypothesized that the conditions that promoted capsule growth would also be associated with an increase in supernatant vesicles. To evaluate the possible correlation between capsule synthesis and vesicle secretion, cryptococci were stimulated to produce capsule, and supernatants were evaluated for vesicle content. Vesicles were obtained by ultracentrifugation at 100,000 g and pellets were resuspended in TBS for GXM analysis by capture ELISA. GXM concentrations in 100,000 g fractions in the different conditions of capsule
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induction were normalized to the number of cells in the culture after each condition of stimulation. In parallel, yeast cells were collected by centrifugation, washed in PBS and fixed in 2% paraformaldehyde for microscopic observation after India ink staining. After 24h of incubation of cryptococci in diluted Sabouraud broth, capsule expression was approximately two-fold higher than that in cells incubated for 6h ( Figure 5A) . Similarly, the content of GXM in the vesicle fraction after 24 h was two-fold higher than that observed after incubation of cryptococci during 6h ( Figure 5B ). GXM also became encapsulated (data not shown), as extensively described in previous studies.
Incorporation of vesicular GXM into
Detection of GXM-containing vesicles from regular cultures or infected macrophages after
sucrose gradient separation. Given the size diversity of the vesicles demonstrated in Figure 1 , a more detailed analysis of vesicle production by C. neoformans during its regular growth was performed by using ultracentrifugation followed by flotation on a step sucrose gradient (15).
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After ultracentrifugation for 18h, twelve fractions were obtained. HPLC analysis revealed the presence of peaks with retention times similar to that of a standard GlcCer in all fractions ( Figure   7A ). The area of each peak varied depending on the sucrose concentration in each fraction.
Analysis of the presence of GXM in sucrose gradient fractions was performed using the capture ELISA test. The results shown in Figure 7B indicate that the maximum indices of polysaccharide detection were measured in the most concentrated sucrose fractions, suggesting that packaging of induces the production of host-derived membrane domains filled with the polysaccharide, as previously suggested (38) . Microscopic analysis of pellets obtained after differential centrifugation of culture supernatants revealed intact vesicles ranging in size from 60-300 nm. Despite this heterogeneity, the vesicles had the common appearance of being rounded and defined by a lipid bilayered membrane.
Differences in electron density were observed, suggesting heterogeneity in vesicular contents.
The size of the vesicles was consistent with those shown in Figure 1 and with the size predicted from the early electron microscopic studies that showed intracellular GXM in what appeared to
be vesicular structures (11, 14, 40) . In those studies, the vesicular structures were 100 to 300 nm in diameter, which is within the range of the vesicles described here.
Glycosphingolipids, sterols and GPI-anchored proteins form detergent-insoluble lipid rafts on the plasma membrane (23). They are required for the processing of surface proteins in yeasts, making part of vesicles that link the RES to Golgi to the plasma membrane (34) . In C.
neoformans, it has been suggested that GlcCer-containing vesicles migrate from the cell membrane to the cell wall (1, 25, 30) . In the present study, lipid analysis by mass spectrometry revealed that a glycosphingolipid (GlcCer) and sterol are components of extracellular vesicles, supporting the idea that they are enriched in lipid rafts. The physiologic production of GlcCer as vesicle components was strengthened by the observation that Sterol derivatives, including ergosterol and an obtusifoliol-like molecule, were also characterized as lipid components of vesicle membranes. Ergosterol and obtusifoliol have been previously described as major sterol components of C. neoformans (18) but, to our knowledge,
this is the first demonstration of 4,14-dimethylergosta-24( 24 1 GXM, the principal capsular polysaccharide of C. neoformans, was detected in vesicle preparations by serological approaches. The possibility that polysaccharide aggregates were contaminating 100,000 g fractions was discarded, since vesicle preparations were purified in a mAb 18B7-bound resin. A definitive association between GXM and vesicles was obtained by immunogold labeling of the vesicles with an anti-GXM antibody followed by TEM analysis, which revealed that the polysaccharide is indeed surrounded by extracellular membrane domains.
This information was supported by the fact that vesicle formation was not an artifact of polysaccharide-mediated effects on lipids ( Figure 4D ) and that the polysaccharide and GlcCer, a lipid marker of cryptococcal vesicles, were concomitantly detected in fractions from a sucrose gradient. In this analysis, the polysaccharide content is directly related to vesicular density, which is in agreement with the high viscosity described for GXM (22) .
McFadden and co-workers have recently provided experimental evidence suggesting that capsule growth involves the production of GXM fibers that are released from, rather than attached to the cell (22) . In this model, capsule construction would depend on the self-association of GXM fibers, in which newly synthesized molecules would be secreted into the extracellular environment and further incorporated throughout the capsule by becoming entangled in existing A C C E P T E D capsular material. A new model of capsule growth was recently proposed whereby the capsule grows by apical extension (41) . Vesicular transport to the capsular edge followed by polysaccharide unloading and polysaccharide self-assembly into a capsule would provide a potential mechanism for apical growth. Such a mechanism may have an inherent error rate such that some vesicles could be released to the extracellular space without unloading and accumulate in the culture supernatant. Alternatively, material destined for capsule or extracellular secretion may be found in different vesicular fractions such that vesicles recovered represent deliberate extra-capsular polysaccharide transport. We, therefore, hypothesized that C. neoformans could release capsular polysaccharides inside vesicles, which would be further lysed by still unknown mechanisms. The fact that the detection of GXM in 100,000 g fractions is higher when capsule expression is more efficient in C. neoformans supports this idea. The observation that acapsular mutants can bind GXM from purified vesicles indicate that C. neoformans is indeed able to lyse vesicles and use its internal content, possibly through the activity of exocellular lipases (5).
Our current results and previous reports (11, 14, 40) indicate that vesicles are synthesized intracellularly and transferred to the cell surface, from where they are secreted to the extracellular environment. It remains unknown how vesicles with an average diameter of 160 nm cross the fungal cell wall, a highly complex and dynamic structure (25) . One possible explanation comes from the observation that the cell wall of Saccharomyces cerevisiae presents regular pores of around 200 nm, which can be increased to 400 nm under stress conditions (7).
Therefore, despite being a rigid and complex structure, the fungal cell wall could allow the passive passage of particles in the range of 60 to 300 nm, dimensions that could accommodate the vesicles described here. Another mechanism for extracellular transport could involve motor proteins. In Aspergillus fumigatus, a 180-kDa polypeptide recognized by anti-myosin antibodies
was found to be concentrated in cell wall and plasma membrane fractions of conidia (9).
Immunoelectron microscopy with an anti-myosin antiserum revealed that the antigen is mainly (38) . In the current study, the distribution of GXM in fractions obtained from ultracentrifugation associated with a sucrose gradient markedly differed when culture fluids of C. neoformans and supernatants from infected macrophages were compared. When macrophage-derived supernatants were analyzed, an additional peak of polysaccharide detection was observed, which could be explained by production of vesicles of different natures during the interaction of C. neoformans these cells, as previously suggested by Tucker and Casadevall (38) . The currently presented data also indicates that C. neoformans produces extracellular vesicles in vivo, supporting the idea that vesicular transport is relevant for polysaccharide release during infection. This result may have 
centrifugation, purified from GXM by affinity chromatography and analyzed by TEM (F-H).
Extracellular vesicles with bilayered membranes and different profiles of electron density were observed. Scale bars correspond to 100 nm in F-G and 50 nm in H. 
living, but not heat-or azide-treated cells. Compounds with migration rates corresponding to an ergosterol standard were detected in 100,000 g fractions from supernatants of living and azidetreated cells, but not in preparations from heat-killed cryptococci. nm. B. The presence of GXM inside the vesicles was confirmed by polysaccharide detection in purified 100,000 g fractions from culture supernatants (white bar). Supernatants obtained from these suspensions were assayed as a control of vesicle integrity and, in fact, GXM was detected at low levels in these preparations (black bar), suggesting that some of these structures may be disrupted. C. GXM content of vesicle suspensions and vesicle-depleted supernatants after serial
44 passage through a column composed of Sepharose-bound mAb 18B7. Sequential passages of vesicle-depleted supernatant through this column results in a rapid loss of reactivity while the GXM content of the vesicular preparation is relatively constant. D. GXM-containing vesicles are not formed extracellularly, since the addition of the polysaccharide to culture supernatants during or after growth of Cap67 cells is not followed by its detection in purified 100,000 g fractions. analyses were performed at least three times, always presenting similar profiles.
